Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 2/20 | 0.62 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 4/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | WEE1 | P30291 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633187 | 0.91 | MTOR (0.60) | MAPK10FGFR4SRCABL1PDGFRB | |
| SCHEMBL1632623 | 0.91 | MAPK10 (0.53) | MAPK10FGFR4SRCABL1PDGFRB | |
| SCHEMBL1634126 | 0.88 | CDK2 (0.49) | MAPK10FGFR4SRCABL1PDGFRB | |
| SCHEMBL1632115 | 0.85 | JAK2 (0.66) | FGFR4JAK2BRD4CDK2CCNA2 | |
| SCHEMBL1633920 | 0.85 | MTOR (0.49) | MAPK10FGFR4SRCABL1PDGFRB | |
| SCHEMBL1632741 | 0.84 | MAPK10 (0.53) | MAPK10CDK2CDK1CCNT1CCNE1 | |
| SCHEMBL1633192 | 0.84 | JAK2 (0.55) | MAPK10FGFR4JAK2BRD4MTOR | |
| SCHEMBL1632775 | 0.83 | MAPK10 (0.51) | MAPK10JAK2CDK2CDK1CCNT1 | |
| SCHEMBL1631876 | 0.83 | CDK2 (0.51) | MAPK10FGFR4SRCABL1PDGFRB | |
| SCHEMBL1633485 | 0.83 | SYK (0.49) | MAPK10JAK2BRD4CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAPK10 402/4885FGFR4 2040/4885SRC 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.